Effects of Upper Extremity Physiotherapy and Home Exercises on Functional Outcomes in Individuals With Stroke
NCT07915141, Not applicable, Not yet recruiting, Istanbul Gelisim University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of Upper Extremity Physiotherapy and Home Exercises on Functional Outcomes in Individuals With Stroke | ClinicalTrials.gov |
| NCT number | NCT07915141 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 42 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Istanbul Gelisim University | ClinicalTrials.gov |
| Conditions | Stroke | ClinicalTrials.gov |
| Interventions | Supervised Upper Extremity Physiotherapy Program, Home Exercise Program | ClinicalTrials.gov |
| First posted | 2026-11-04 | ClinicalTrials.gov |
| Last updated | 2026-11-04 | ClinicalTrials.gov |
Registered outcomes 5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Barthel Index Score | Baseline (Week 1) and post-intervention (Week 10) | The Barthel Index is used to assess independence in activities of daily living. Total scores range from 0 to 100, with higher scores indicating greater functional independence. Changes in Barthel Index scores from baseline to the end of the 10-week intervention are compared between the intervention and control groups. | ClinicalTrials.gov |
| Primary | Change in SF-36 Quality of Life Scores | Baseline (Week 1) and post-intervention (Week 10) | The SF-36 is used to assess health-related quality of life across eight domains. Scores for each domain range from 0 to 100, with higher scores indicating better health-related quality of life. Changes in scores from baseline to the end of the 10-week intervention are compared between the two groups. | ClinicalTrials.gov |
| Secondary | Change in Upper Extremity Range of Motion (ROM) | Baseline (Week 1) and post-intervention (Week 10) | Upper extremity range of motion is assessed using a goniometer. Measurements include shoulder flexion, extension and abduction; elbow flexion and extension; and wrist flexion and extension. Range of motion is recorded in degrees (°), with higher values indicating greater joint mobility. Changes from baseline to Week 10 are compared between the two groups. | ClinicalTrials.gov |
| Secondary | Change in Pain Intensity Measured by Visual Analog Scale (VAS) | Baseline (Week 1) and post-intervention (Week 10) | Pain intensity is assessed using the Visual Analog Scale (VAS), a 10-cm scale ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Changes in VAS scores from baseline to the end of the 10-week intervention are compared between the intervention and control groups. | ClinicalTrials.gov |
| Secondary | Change in Upper Extremity Sensory Function | Baseline (Week 1) and post-intervention (Week 10) | Upper extremity sensory function is assessed using superficial, deep, and cortical sensory tests, including temperature discrimination, sharp-dull discrimination, joint position sense (proprioception), and stereognosis. Changes in sensory function from baseline to Week 10 are evaluated in both groups. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)